Mersana stock falls after cancer drug data (MRSN:NASDAQ) | Seeking Alpha
Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in solid tumors.
Leap Therapeutics stock tumbles after mid-stage trial setback
Leap Therapeutics (LPTX) shares fell after the company announced a setback in its mid-stage clinical trial for a cancer treatment.
Telix kidney cancer imaging agent granted FDA priority review
Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET[1] imaging agent TLX250-CDx (Zircaix¨[2], 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA[3] date of 27 August 2025, paving the way for a U.S. commercial launch in 2025.
Lilly, AdvanCell to collaborate on alpha treatments for cancer
Eli Lilly (NYSE:LLY) and AdvanCell have agreed to work together on developing alpha therapies for the treatment of cancer.
Pfizer, Astellas Padcev combo shows overall survival benefit in urothelial cancer
A combination of pfizer (NYSE:PFE)and Astellas` (OTCPK:ALPMF) (OTCPK:ALPMY) antibody-drug conjugate Padcev (enfortumab vedotin-rjfv) with Merck`s (MRK) keytruda (pembrolizumab) demonstrated a ustained overall survival and progression-free survival benefit as afirst-line theraphy for urothelial cancer.
Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer
Acrivon Therapeutics (NASDAQ:ACRV) announced the U.S. FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay, a multiplex immunofluorescence assay for the identification of endometrial cancer patients who may benefit from ACR-368 treatment.
Breast cancer: Three times I learnt my diet was wrong – and how to avoid my mistakes
A breast cancer survivor shares her experiences with dietary mistakes during treatment and offers advice on proper nutrition.
Leap scraps late-stage plans for gastric cancer therapy after mid-stage setback
Leap Therapeutics (NASDAQ:LPTX) lost 63% in the premarket on Tuesday after the antibody-based drug developer announced that it would not advance its lead candidate, sirexatamab, in Phase 3 studies for gastric cancer following disappointing data from a mid-stage trial.
asy Breakfast Ideas That May Lower Your Cancer Risk
Discover simple and nutritious breakfast recipes that could help reduce the risk of cancer, according to nutrition experts.
Pfizer succeeds in late-stage trial for colorectal cancer therapy
Pfizer (NYSE:PFE) announced Saturday that its colorectal cancer therapy Braftovi, as part of a combination regimen, reduced tumor size (confirmed objective response rate) in a late-stage trial with a clinically meaningful and statistically significant effect.
Bristol Myers colorectal cancer drug cuts relapse risk (BMY) | Seeking Alpha
Bristol Myers Squibb (BMY) says its cancer drugs Opdivo and Yervoy improved progression-free survival in a Phase 3 trial for certain colorectal cancer. Read more here.
Merck and Eisai announce positive Phase 3 results for Keytruda and Lenvima combination
The combination of Keytruda and Lenvima met primary endpoints in a Phase 3 trial, showing significant improvement in overall survival for patients with advanced cancers.
